Back to top
more

The Pennant Group (PNTG)

(Delayed Data from NSDQ)

$20.69 USD

20.69
121,086

-0.09 (-0.43%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $20.69 0.00 (0.00%) 7:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Makes The Pennant Group, Inc. (PNTG) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does The Pennant Group, Inc. (PNTG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Tenet Healthcare (THC) Soars 76% in a Year: What Lies Ahead?

by Zacks Equity Research

Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.

Humana (HUM), DUOS Unveil Program to Improve Veterans' Health

by Zacks Equity Research

Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.

Here's Why The Pennant Group, Inc. (PNTG) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does The Pennant Group, Inc. (PNTG) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes The Pennant Group, Inc. (PNTG) a New Buy Stock

by Zacks Equity Research

The Pennant Group, Inc. (PNTG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The Pennant Group, Inc. (PNTG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for The Pennant Group, Inc. (PNTG) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ahead of The Pennant Group, Inc. (PNTG) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of The Pennant Group, Inc. (PNTG) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

DaVita HealthCare (DVA) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 22.22% and 4.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics (DGX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.47% and 1.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

The Pennant Group, Inc. (PNTG) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

The Pennant Group, Inc. (PNTG) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Annexon, NVIDIA, Intuit in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Should Value Investors Buy DaVita (DVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Pennant Group, Inc. (PNTG) Surges 8.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

The Pennant Group, Inc. (PNTG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.

Should Value Investors Buy DaVita (DVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Pennant Group, Inc. (PNTG) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Are Investors Undervaluing The Pennant Group (PNTG) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Pennant Group, Inc. (PNTG) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

The Pennant Group, Inc. (PNTG) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Humana (HUM) Extends CINQCARE's Home Care Model to MA Members

by Zacks Equity Research

Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.

Zacks Industry Outlook Highlights DaVita, Option Care Health, Addus HomeCare and Pennant

by Zacks Equity Research

DaVita, Option Care Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.

Debanjana Dey headshot

4 Stocks to Watch in an Evolving Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, OPCH, ADUS and PNTG are well-poised to gain.

Should Value Investors Buy The Pennant Group (PNTG) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Fast-paced Momentum Stock The Pennant Group, Inc. (PNTG) Is Still Trading at a Bargain

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, The Pennant Group, Inc. (PNTG) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Here's What Key Metrics Tell Us About The Pennant Group, Inc. (PNTG) Q3 Earnings

by Zacks Equity Research

The headline numbers for The Pennant Group, Inc. (PNTG) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Encompass Health (EHC) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Encompass Health (EHC) delivered earnings and revenue surprises of 11.69% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?